“…Dysfunction of the dopaminergic system has been implicated in motor disturbances (e.g., Parkinson’s disease, Huntington’s disease, and Alzheimer’s disease (Jahanshahi et al, 2013; Michel et al, 2013; Reeves et al, 2010) as well as in OCD (Denys et al, 2004; Hesse et al, 2005; Nikolaus et al, 2010; Olver et al, 2009), and dysfunction of the serotonergic system has been implicated in OCD and anxiety disorders (Flaisher-Grinberg et al, 2008; Hesse et al, 2005; Hesse et al, 2011; Nikolaus et al, 2010; Perani et al, 2008). Dopaminergic and serotonergic drugs are used to treat motor and psychiatric symptoms, respectively, in patients affected by GAS-related neuropsychiatric disorders (Demiroren et al, 2007; Gabbay and Coffey, 2003; Moretti et al, 2008; Murphy et al, 2010; Swedo and Grant, 2005; Swedo et al, 1993). Finally, immunoreactivity to different components of the serotonergic system, such as serotonin and serotonin receptors, has been reported in sera from panic disorder and rheumatoid arthritis patients (Coplan et al, 1999; Maes et al, 2013; Schott et al, 2003; Tanaka et al, 2003), and sera from SC and PANDAS patients reacted with D1 and D2 receptors (Brimberg et al, 2012; Cox et al, 2013; Dale et al, 2012).…”